Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2014

View Archived Issues

Researchers describe mechanism of action of ProHema

Acucela completes enrollment in SEATTLE study of emixustat

Targeting the self-renewal of cancer-initiating cells as a new approach for colorectal cancer

Janssen Pharmaceutica designs new agents for pain

Novel SYK inhibitors synthesized at Novartis

Proteostasis Therapeutics and Cystic Fibrosis Foundation Therapeutics extend collaboration

Cellectar Biosciences begins phase II imaging trial of [124I]CLR-1404

Genticel begins phase II trial in women with high-risk HPV

New milestone reached in Genfit and Sanofi's research collaboration

Viriom begins new program for chronic hepatitis B

International Stem Cell reports interim data from stem cell primate study for Parkinson's disease

Astex receives milestone payment as LEE-011 enters phase III trial

Eisai and Biogen Idec to collaborate in Alzheimer's disease

High 12-week sustained virological response rates in PEARL III study

Vaginal dapivirine effectively protects against HIV challenge

Novartis reports novel SMN modulators for spinal muscular atrophy

New KOR-1 antagonists patented by the Scripps Research Institute

FDA accepts additional Lymphoseek supplemental NDA for review

Kamada initiates phase II/III trials with intravenous Glassia for the treatment of type 1 diabetes

FDA issues complete response letter for empagliflozin

Next-generation sequencing for a rare cancer

Janssen Biotech to begin phase III study of daratumumab in multiple myeloma

FDA grants fast track designation to Tekmira's TKM-Ebola

Regulus Therapeutics initiates phase I study of RG-101

Agenus selects modulator antibodies to advance into preclinical development

iCo Therapeutics updates progress of iDEAL study of iCo-007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...